Pressure BioSciences (OTCQB: PBIO), a leader in the development and sale of innovative, broadly enabling, pressure-based instruments, consumables, and specialty testing services to the worldwide life sciences, nutraceuticals, cosmetics, food and beverage, and other key industries, is presenting at today’s Emerging Growth Investor Conference. The conference has built a reputation for being an effective way for publicly traded companies to present and communicate new products and services as well as other major announcements to thousands of individual and institutional investors and investment advisors and analysts. PBI president and CEO Richard T. Schumacher spoke at 9 a.m. ET; the focus of his presentation was on the much-anticipated commercial launch of the company’s Ultra Shear Technology(TM) (“UST”) nanoemulsification platform. Throughout the past few months, Pressure BioSciences has entered three agreements covering the production, distribution, commercial roll-out and financial partnership for novel, effectively water-soluble, highly bioavailable, nanoemulsified CBD products for both oral and topical use; the company also has entered a cosmeceuticals partnership with Dr. Denese SkinScience, a 20-year skincare industry leader with more than $500 million in QVC sales. “All four contracts are based on the use of the UST platform to develop nanoemulsions of oil-based nutraceuticals and cosmetics,” the company stated in the press release. “Nanoemulsions are known to turn oil-based active ingredient mixtures (e.g., CBD, THC, astaxanthin, curcumin, retinol, prednisone) into long-term stable, effectively water-soluble, highly bioavailable formulations. The company believes these four contracts alone could generate over $5 million of accretive revenue for PBI in 2023. The company plans to close on a minimum of six additional contracts over the remaining months of FY 2022, further adding to 2023 revenue.”
To view the full press release, visit https://ibn.fm/PIe9N
About Pressure BioSciences Inc.
Pressure BioSciences is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences and other industries. PBIO’s products are based on the unique properties of both constant (i.e., static) and alternating, or pressure cycling technology (“PCT”) hydrostatic pressure. PCT is a patented-enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control biomolecular interactions (e.g., cell lysis, biomolecule extraction). The company’s primary focus is on the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil and plant biology, forensics and counter-bioterror applications. Additionally, major new market opportunities have emerged for the use of PBIO’s pressure-based technologies in the following areas: (1) the use of its recently acquired, patented technology from BaroFold Inc. (the “BaroFold” technology) to allow entry into the bio-pharma contract services sector, and (2) the use of its recently patented, scalable, high-efficiency, pressure-based Ultra Shear Technology platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room-temperature, stable, low-acid liquid foods that cannot be effectively preserved using existing nonthermal technologies. For more information, visit the company website at www.PressureBioSciences.com.
NOTE TO INVESTORS: The latest news and updates relating to PBIO are available in the company’s newsroom at http://ibn.fm/PBIO
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork.
